These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33842645)

  • 1. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
    Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
    Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
    Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
    Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
    Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
    JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracranial response to capmatinib after progression on crizotinib in a patient with
    Jóri B; Bundschuh O; Falk M; Heukamp LC; Kluge A; Tiemann M; Willborn KC; Woitzik J; Griesinger F
    Transl Lung Cancer Res; 2024 Jul; 13(7):1749-1755. PubMed ID: 39118880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
    Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
    J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future treatment options for
    Hong L; Zhang J; Heymach JV; Le X
    Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
    Tian J; Lin Z; Chen Y; Fu Y; Ding Z
    Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
    Kato Y; Yamamoto G; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Seike M; Gemma A; Akagi K; Sakai H
    Int J Clin Oncol; 2021 Jun; 26(6):1065-1072. PubMed ID: 33660106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
    Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
    Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
    Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
    Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
    Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
    Front Oncol; 2021; 11():649766. PubMed ID: 34249687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.
    Meng Y; Zhou W; Li C; Zhou X; Li X; Li L; Fu Q; Huang J; Yue Y; Shen X; Yang L; Wang M
    Front Oncol; 2024; 14():1383964. PubMed ID: 39015492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
    Spitaleri G; Trillo Aliaga P; Attili I; Del Signore E; Corvaja C; Corti C; Uliano J; Passaro A; de Marinis F
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.